Sarepta Therapeutics (NASDAQ:SRPT)

CAPS Rating: 2 out of 5

A biopharmaceutical company developing therapeutic products principally based on third-generation NEUGENE antisense technology.

Recs

0
Player Avatar StockTraderG (93.05) Submitted: 10/3/2012 11:49:09 AM : Outperform Start Price: $15.36 SRPT Score: +91.85

Big Data coming

Report this Post 1 Reply
Member Avatar jc07 (63.86) Submitted: 10/5/2012 10:12:29 AM
Recs: 0

This man is a wizard

Report this Post

Featured Broker Partners


Advertisement